Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Evgen Pharma RNS Release

Hardman Res.: Funded to the end of Phase II trials


RNS Number : 8875Y
Evgen Pharma PLC
11 December 2017
 

Hardman Research: Funded to the end of Phase II trials

Increased funding to the end of Phase II trials : Evgen is a virtual pharmaceutical company focused on the development of a synthetic version of a natural product, sulforaphane, which is known to modulate key signalling pathways involved in cellular protection and inflammation. Evgen's proprietary technology, Sulforadex, creates new and stable variants of sulforaphane, enabling it to be used as a therapeutic for the first time. SFX-01 is progressing in Phase II clinical trials for both subarachnoid haemorrhage and ER+ breast cancer, with readouts expected in or around the end of 2018. EVG has strengthened its balance sheet with a Placing to raise new funds of £2.3m gross.

Please click here for the full report:

http://hardmanandco.com/docs/default-source/company-docs/evgen-pharma-documents/11.12.17-funded-to-the-end-of-phase-ii-trials.pdf

To contact us:   

Hardman & Co

35 New Broad Street

London

EC2M 1NH

Analysts:

Dr Martin Hall  [email protected]

Dr Dorothea Hill  [email protected]

Dr Gregoire Pave  [email protected]

Telephone: +44 20 7194 7622

Follow us on Twitter @HardmanandCo

www.hardmanandco.com

About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies.  It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRABIBDDXDGBGRI

Evgen Pharma Timeline

Article
October 21 2015

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use